FDA Recall: Baxter Cefazolin IV Bags With Cardboard Particles—Next Steps
FDA says Baxter is voluntarily recalling one lot of cefazolin in dextrose IV bags after cardboard-like particles were found in the solution. If you still have the product, stop using it and return it as instructed. If you received it during surgery, contact your facility for lot-specific information—and seek emergency care for symptoms that could signal a pulmonary embolism (like sudden shortness of breath or chest pain).
FDA is warning about a voluntary nationwide recall of one lot of an IV antibiotic: cefazolin in dextrose (Baxter). The issue is that cardboard-like particulate matter was found in the solution inside the IV bags.
This recall is meant to protect patients and healthcare staff by preventing potentially contaminated product from being used. If you received this medication during surgery, you do not need to panic—but you should contact the facility that gave you the dose to confirm whether it was from the affected lot.
Quick recall snapshot
- Company announcement / FDA publish date: July 24, 2026
- What was recalled: Baxter Cefazolin in Dextrose Injection, USP, 2 g / 100 mL (20 mg/mL), single-dose infusion bag in a 100 mL GALAXY plastic container (frozen premix)
- Recall reason: particulate matter found in the solution, identified as cardboard
- Affected lot: LD175708
- Expiration: 14-Feb-2027
- NDC: 0338-3508-41
- Distribution window (U.S.): 3/25/2025 to 6/30/2025
Why cardboard particles matter in an IV antibiotic
In general, foreign material in an IV medication is taken seriously because it can be infused into the bloodstream.
In FDA’s summary of Baxter’s risk statement, use of the defective product is described as having a reasonable probability of causing serious complications, including:
- Pulmonary emboli (blockage in pulmonary blood vessels)
- Occlusions of other blood vessels (which can lead to tissue death and possible organ damage)
- Phlebitis (inflammation of vein walls, which may lead to clotting)
Systemically, the risk statement also describes possible effects such as immune system activation, organ dysfunction, and hemolysis (breakdown of blood cells). FDA notes that, as of July 24, 2026, Baxter had not received any reports of adverse events related to this issue.
If you still have the product
This recall is aimed primarily at healthcare settings that received and stocked the affected IV bags. If your facility handles or dispenses this medication:
- Do not use affected units.
- Return affected units following your facility’s process. Baxter is contacting customers with instructions to identify and return the impacted product.
If you are a patient or caregiver, the most practical next step is to ask the facility whether you were given a dose from the recalled lot.
If you already received it during surgery
Do not guess—ask for lot-specific information.
- Contact the surgical team, hospital pharmacy, or outpatient infusion staff that provided the medication.
- Ask whether the unit administered was from Lot LD175708 (exp 14-Feb-2027).
- If you were already discharged, ask how to report symptoms and how the facility documents exposure to recalled product.
Symptoms that should trigger urgent/emergency care
Because FDA’s risk statement includes pulmonary embolism, be alert for symptoms of possible blood clots in the lungs after surgery (or during recovery). Seek emergency care right away (call 911 or go to the ER) if you develop:
- Sudden shortness of breath
- Rapid breathing
- Chest pain or discomfort (often worse with coughing or taking a deep breath)
- Increased heart rate
- Coughing up blood
- Lightheadedness, fainting, or very low blood pressure
These symptoms can have multiple causes after surgery, but they should not be ignored. Emergency clinicians can assess what’s going on and whether urgent testing or treatment is needed.
What’s known—and what’s not yet known
- Known: FDA lists a voluntary nationwide recall of one Baxter lot (LD175708, exp 14-Feb-2027) due to cardboard particulate found in the solution.
- Known: FDA reports that, as of July 24, 2026, Baxter had not received adverse event reports related to this issue.
- Known: The medication is used intravenously to treat bacterial infections or help prevent infection during surgery.
- Not yet known: The recall notice does not tell readers how often (if at all) this specific particulate issue leads to real-world harm in everyday practice.
- Not yet known: The actual risk can depend on factors such as particle characteristics, patient conditions, and how the product was prepared and administered.
Questions to ask your clinician or pharmacist
- Was any dose I received from the affected lot (LD175708)?
- Can the facility confirm the lot number used for my surgery or treatment?
- If I develop symptoms like sudden shortness of breath or chest pain, what is the fastest way to reach the right team?
- If I’m worried about exposure, is any follow-up monitoring recommended based on my surgery and medical history?
Key sources
- MedlinePlus: Pulmonary Embolism (symptoms/red flags)
- CDC: Surgical Site Infection (SSI) prevention (perioperative infection prevention context)
- IDSA Guideline (Antimicrobial Prophylaxis in Surgery) PDF
- Visible Particles Review (peer-reviewed background on particulate contamination safety considerations)
Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.
This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.
